{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T14:09:04Z","timestamp":1789826944911,"version":"4.0.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]},{"name":"Cardiovascular Alliance for Dyslipidemia and Arteriosclerosis and the Fundamental Research Funds for the Central Universities of the Xi\u2019an Jiaotong University","award":["No. xzy022020044"],"award-info":[{"award-number":["No. xzy022020044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"DOI":"10.1186\/s12944-024-02398-1","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T11:10:47Z","timestamp":1734606647000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effects of Probucol on plasma amyloid-\u03b2 transport in patients with hyperlipidemia: a 12-week randomized, double-blind, placebo-controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Liangjun","family":"Dang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhang","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiumin","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"key":"2398_CR1","doi-asserted-by":"publisher","first-page":"e661","DOI":"10.1016\/S2468-2667(20)30185-7","volume":"5","author":"L Jia","year":"2020","unstructured":"Jia L, Du Y, Chu L, Zhang Z, Li F, Lyu D, Li Y, Li Y, Zhu M, Jiao H, et al. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: a cross-sectional study. Lancet Public Health. 2020;5:e661\u201371.","journal-title":"Lancet Public Health"},{"key":"2398_CR2","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3233\/JAD-180903","volume":"67","author":"GT Grossberg","year":"2019","unstructured":"Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for alzheimer\u2019s disease. J Alzheimers Dis. 2019;67:1157\u201371.","journal-title":"J Alzheimers Dis"},{"key":"2398_CR3","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3233\/JAD-160826","volume":"56","author":"KJ Anstey","year":"2017","unstructured":"Anstey KJ, Ashby-Mitchell K, Peters R. updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis. 2017;56:215\u201328.","journal-title":"J Alzheimers Dis"},{"key":"2398_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00406-013-0468-2","volume":"264","author":"P Toro","year":"2014","unstructured":"Toro P, Degen C, Pierer M, Gustafson D, Schr\u00f6der J, Sch\u00f6nknecht P. Cholesterol in mild cognitive impairment and Alzheimer\u2019s disease in a birth cohort over 14 years. Eur Arch Psychiatry Clin Neurosci. 2014;264:485\u201392.","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"2398_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jalz.2016.08.003","volume":"13","author":"P Proitsi","year":"2017","unstructured":"Proitsi P, Kim M, Whiley L, Simmons A, Sattlecker M, Velayudhan L, Lupton MK, Soininen H, Kloszewska I, Mecocci P, et al. Association of blood lipids with Alzheimer\u2019s disease: A comprehensive lipidomics analysis. Alzheimers Dement. 2017;13:140\u201351.","journal-title":"Alzheimers Dement"},{"key":"2398_CR6","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science. 2002;297:353\u20136.","journal-title":"Science"},{"key":"2398_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC, Dickson DW, Duyckaerts C, Frosch MP, Masliah E, et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 2012;8:1\u201313.","journal-title":"Alzheimers Dement"},{"key":"2398_CR8","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","volume":"7","author":"RA Sperling","year":"2011","unstructured":"Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR Jr, Kaye J, Montine TJ, et al. Toward defining the preclinical stages of Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:280\u201392.","journal-title":"Alzheimers Dement"},{"key":"2398_CR9","doi-asserted-by":"publisher","first-page":"795","DOI":"10.3233\/JAD181028","volume":"67","author":"A Serrano-Pozo","year":"2019","unstructured":"Serrano-Pozo A, Growdon JH. Is Alzheimer\u2019s Disease Risk Modifiable? J Alzheimers Dis. 2019;67:795\u2013819.","journal-title":"J Alzheimers Dis"},{"key":"2398_CR10","doi-asserted-by":"crossref","unstructured":"Kao YC, Ho PC, Tu YK, Jou IM, Tsai KJ. Lipids and Alzheimer\u2019s Disease. Int J Mol Sci. 2020;21:1505\u201342.","DOI":"10.3390\/ijms21041505"},{"key":"2398_CR11","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1002\/alz.12000","volume":"16","author":"J Kaplow","year":"2020","unstructured":"Kaplow J, Vandijck M, Gray J, Kanekiyo M, Huyck E, Traynham CJ, Esquivel R, Fagan AM, Luthman J. Concordance of Lumipulse cerebrospinal fluid t-tau\/A\u03b242 ratio with amyloid PET status. Alzheimers Dement. 2020;16:144\u201352.","journal-title":"Alzheimers Dement"},{"key":"2398_CR12","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1001\/jama.2019.2000","volume":"321","author":"GD Rabinovici","year":"2019","unstructured":"Rabinovici GD, Gatsonis C, Apgar C, Chaudhary K, Gareen I, Hanna L, Hendrix J, Hillner BE, Olson C, Lesman-Segev OH, et al. Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321:1286\u201394.","journal-title":"JAMA"},{"key":"2398_CR13","doi-asserted-by":"publisher","first-page":"e1647","DOI":"10.1212\/WNL.0000000000008081","volume":"93","author":"SE Schindler","year":"2019","unstructured":"Schindler SE, Bollinger JG, Ovod V, Mawuenyega KG, Li Y, Gordon BA, Holtzman DM, Morris JC, Benzinger TLS, Xiong C, et al. High-precision plasma \u03b2-amyloid 42\/40 predicts current and future brain amyloidosis. Neurology. 2019;93:e1647\u201359.","journal-title":"Neurology"},{"key":"2398_CR14","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","volume":"13","author":"V Ovod","year":"2017","unstructured":"Ovod V, Ramsey KN, Mawuenyega KG, Bollinger JG, Hicks T, Schneider T, Sullivan M, Paumier K, Holtzman DM, Morris JC, et al. Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 2017;13:841\u20139.","journal-title":"Alzheimers Dement"},{"key":"2398_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/nature25456","volume":"554","author":"A Nakamura","year":"2018","unstructured":"Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Dor\u00e9 V, Fowler C, Li QX, Martins R, Rowe C, et al. High performance plasma amyloid-\u03b2 biomarkers for Alzheimer\u2019s disease. Nature. 2018;554:249\u201354.","journal-title":"Nature"},{"key":"2398_CR16","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrneurol.2015.119","volume":"11","author":"JM Tarasoff-Conway","year":"2015","unstructured":"Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, et al. Clearance systems in the brain-implications for Alzheimer disease. Nat Rev Neurol. 2015;11:457\u201370.","journal-title":"Nat Rev Neurol"},{"key":"2398_CR17","doi-asserted-by":"publisher","first-page":"45897","DOI":"10.1074\/jbc.M407668200","volume":"279","author":"J Ghiso","year":"2004","unstructured":"Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B. Systemic catabolism of Alzheimer\u2019s Abeta40 and Abeta42. J Biol Chem. 2004;279:45897\u2013908.","journal-title":"J Biol Chem"},{"key":"2398_CR18","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1038\/mp.2017.204","volume":"23","author":"XL Bu","year":"2018","unstructured":"Bu XL, Xiang Y, Jin WS, Wang J, Shen LL, Huang ZL, Zhang K, Liu YH, Zeng F, Liu JH, et al. Blood-derived amyloid-\u03b2 protein induces Alzheimer\u2019s disease pathologies. Mol Psychiatry. 2018;23:1948\u201356.","journal-title":"Mol Psychiatry"},{"key":"2398_CR19","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1179\/135100008X259196","volume":"13","author":"D Tanous","year":"2008","unstructured":"Tanous D, Hime N, Stocker R. Anti-atherosclerotic and anti-diabetic properties of probucol and related compounds. Redox Rep. 2008;13:48\u201359.","journal-title":"Redox Rep"},{"key":"2398_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1084\/jem.20060218","volume":"203","author":"JW Heinecke","year":"2006","unstructured":"Heinecke JW. Lipoprotein oxidation in cardiovascular disease: chief culprit or innocent bystander? J Exp Med. 2006;203:813\u20136.","journal-title":"J Exp Med"},{"key":"2398_CR21","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11745-011-3595-4","volume":"47","author":"MM Pallebage-Gamarallage","year":"2012","unstructured":"Pallebage-Gamarallage MM, Galloway S, Takechi R, Dhaliwal S, Mamo JC. Probucol suppresses enterocytic accumulation of amyloid-\u03b2 induced by saturated fat and cholesterol feeding. Lipids. 2012;47:27\u201334.","journal-title":"Lipids"},{"key":"2398_CR22","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/j.expneurol.2011.11.036","volume":"233","author":"DB Santos","year":"2012","unstructured":"Santos DB, Peres KC, Ribeiro RP, Colle D, dos Santos AA, Moreira EL, Souza DO, Figueiredo CP, Farina M. Probucol, a lipid-lowering drug, prevents cognitive and hippocampal synaptic impairments induced by amyloid \u03b2 peptide in mice. Exp Neurol. 2012;233:767\u201375.","journal-title":"Exp Neurol"},{"key":"2398_CR23","doi-asserted-by":"publisher","first-page":"923","DOI":"10.2217\/nnm-2023-0092","volume":"18","author":"SR Wagle","year":"2023","unstructured":"Wagle SR, Ionescu CM, Kovacevic B, Jones M, Foster T, Lim P, Lewkowicz M, \u00d0ani\u0107 M, Mikov M, Mooranian A, Al-Salami H. Pharmaceutical characterization of probucol bile acid-lithocholic acid nanoparticles to prevent chronic hearing related and similar cellular oxidative stress pathologies. Nanomedicine (Lond). 2023;18:923\u201340.","journal-title":"Nanomedicine (Lond)"},{"key":"2398_CR24","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/1479164118795274","volume":"16","author":"JC Mamo","year":"2019","unstructured":"Mamo JC, Lam V, Brook E, Mooranian A, Al-Salami H, Fimognari N, Nesbit M, Takechi R. Probucol prevents blood-brain barrier dysfunction and cognitive decline in mice maintained on pro-diabetic diet. Diab Vasc Dis Res. 2019;16:87\u201397.","journal-title":"Diab Vasc Dis Res"},{"key":"2398_CR25","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.jalz.2014.07.156","volume":"11","author":"MC Donohue","year":"2015","unstructured":"Donohue MC, Moghadam SH, Roe AD, Sun CK, Edland SD, Thomas RG, Petersen RC, Sano M, Galasko D, Aisen PS, Rissman RA. Longitudinal plasma amyloid beta in Alzheimer\u2019s disease clinical trials. Alzheimers Dement. 2015;11:1069\u201379.","journal-title":"Alzheimers Dement"},{"key":"2398_CR26","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.chroma.2018.07.018","volume":"1568","author":"SH Kim","year":"2018","unstructured":"Kim SH, Yang JS, Lee JC, Lee JY, Lee JY, Kim E, Moon MH. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer\u2019s disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2018;1568:91\u2013100.","journal-title":"J Chromatogr A"},{"key":"2398_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1006\/nbdi.2000.0304","volume":"7","author":"LM Refolo","year":"2000","unstructured":"Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA. Hypercholesterolemia accelerates the Alzheimer\u2019s amyloid pathology in a transgenic mouse model. Neurobiol Dis. 2000;7:321\u201331.","journal-title":"Neurobiol Dis"},{"key":"2398_CR28","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/jnnp.2008.150433","volume":"80","author":"MD Haag","year":"2009","unstructured":"Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity The Rotterdam Study. J Neurol Neurosurg Psychiatry. 2009;80:13\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"2398_CR29","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1212\/01.wnl.0000277657.95487.1c","volume":"69","author":"G Li","year":"2007","unstructured":"Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, Peskind ER, Raskind MA, Breitner JC, Montine TJ. Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology. 2007;69:878\u201385.","journal-title":"Neurology"},{"key":"2398_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.expneurol.2009.07.024","volume":"223","author":"P Lewczuk","year":"2010","unstructured":"Lewczuk P, Kornhuber J, Vanmechelen E, Peters O, Heuser I, Maier W, Jessen F, B\u00fcrger K, Hampel H, Fr\u00f6lich L, et al. Amyloid beta peptides in plasma in early diagnosis of Alzheimer\u2019s disease: A multicenter study with multiplexing. Exp Neurol. 2010;223:366\u201370.","journal-title":"Exp Neurol"},{"key":"2398_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1001\/archneur.64.3.354","volume":"64","author":"NR Graff-Radford","year":"2007","unstructured":"Graff-Radford NR, Crook JE, Lucas J, Boeve BF, Knopman DS, Ivnik RJ, Smith GE, Younkin LH, Petersen RC, Younkin SG. Association of low plasma Abeta42\/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch Neurol. 2007;64:354\u201362.","journal-title":"Arch Neurol"},{"key":"2398_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.neurobiolaging.2006.03.004","volume":"27","author":"M Pesaresi","year":"2006","unstructured":"Pesaresi M, Lovati C, Bertora P, Mailland E, Galimberti D, Scarpini E, Quadri P, Forloni G, Mariani C. Plasma levels of beta-amyloid (1\u201342) in Alzheimer\u2019s disease and mild cognitive impairment. Neurobiol Aging. 2006;27:904\u20135.","journal-title":"Neurobiol Aging"},{"key":"2398_CR33","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1001\/jama.2010.1995","volume":"305","author":"K Yaffe","year":"2011","unstructured":"Yaffe K, Weston A, Graff-Radford NR, Satterfield S, Simonsick EM, Younkin SG, Younkin LH, Kuller L, Ayonayon HN, Ding J, Harris TB. Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline. JAMA. 2011;305:261\u20136.","journal-title":"JAMA"},{"key":"2398_CR34","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1017\/S1461145701002310","volume":"4","author":"LT Friedhoff","year":"2001","unstructured":"Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int J Neuropsychopharmacol. 2001;4:127\u201330.","journal-title":"Int J Neuropsychopharmacol"},{"key":"2398_CR35","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1001\/archneur.61.3.333","volume":"61","author":"K H\u00f6glund","year":"2004","unstructured":"H\u00f6glund K, Wiklund O, Vanderstichele H, Eikenberg O, Vanmechelen E, Blennow K. Plasma levels of beta-amyloid(1\u201340), beta-amyloid(1\u201342), and total beta-amyloid remain unaffected in adult patients with hypercholesterolemia after treatment with statins. Arch Neurol. 2004;61:333\u20137.","journal-title":"Arch Neurol"},{"key":"2398_CR36","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1111\/1440-1681.12032","volume":"40","author":"R Takechi","year":"2013","unstructured":"Takechi R, Galloway S, Pallebage-Gamarallage MM, Lam V, Dhaliwal SS, Mamo JC. Probucol prevents blood-brain barrier dysfunction in wild-type mice induced by saturated fat or cholesterol feeding. Clin Exp Pharmacol Physiol. 2013;40:45\u201352.","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"2398_CR37","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1038\/nm1635","volume":"13","author":"A Sagare","year":"2007","unstructured":"Sagare A, Deane R, Bell RD, Johnson B, Hamm K, Pendu R, Marky A, Lenting PJ, Wu Z, Zarcone T, et al. Clearance of amyloid-beta by circulating lipoprotein receptors. Nat Med. 2007;13:1029\u201331.","journal-title":"Nat Med"},{"key":"2398_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3233\/JAD-2010-101248","volume":"24","author":"AP Sagare","year":"2011","unstructured":"Sagare AP, Deane R, Zetterberg H, Wallin A, Blennow K, Zlokovic BV. Impaired lipoprotein receptor-mediated peripheral binding of plasma amyloid-\u03b2 is an early biomarker for mild cognitive impairment preceding Alzheimer\u2019s disease. J Alzheimers Dis. 2011;24:25\u201334.","journal-title":"J Alzheimers Dis"},{"key":"2398_CR39","doi-asserted-by":"crossref","unstructured":"Koyama A, Stone K, Yaffe K. Serum oxidized low-density lipoprotein level and risk of cognitive impairment in older women. Neurobiol Aging. 2013;34:634\u221235.","DOI":"10.1016\/j.neurobiolaging.2012.02.030"},{"key":"2398_CR40","doi-asserted-by":"crossref","unstructured":"Kassner SS, Bonaterra GA, Kaiser E, Hildebrandt W, Metz J, Schr\u00f6der J, Kinscherf R. Novel systemic markers for patients with Alzheimer disease? - a pilot study. Curr Alzheimer Res. 2008;5:358\u221266.","DOI":"10.2174\/156720508785132253"},{"key":"2398_CR41","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.freeradbiomed.2014.07.012","volume":"75","author":"IH Dias","year":"2014","unstructured":"Dias IH, Mistry J, Fell S, Reis A, Spickett CM, Polidori MC, Lip GY, Griffiths HR. Oxidized LDL lipids increase \u03b2-amyloid production by SH-SY5Y cells through glutathione depletion and lipid raft formation. Free Radic Biol Med. 2014;75:48\u201359.","journal-title":"Free Radic Biol Med"},{"key":"2398_CR42","doi-asserted-by":"crossref","unstructured":"Aldred S, Bennett S, Mecocci P. Increased low-density lipoprotein oxidation, but not total plasma protein oxidation, in Alzheimer\u2019s disease. Clin Biochem. 2010;43:267\u221271.","DOI":"10.1016\/j.clinbiochem.2009.08.021"},{"key":"2398_CR43","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3233\/JAD-180098","volume":"63","author":"Z Cai","year":"2018","unstructured":"Cai Z, Qiao PF, Wan CQ, Cai M, Zhou NK, Li Q. Role of Blood-Brain Barrier in Alzheimer\u2019s Disease. J Alzheimers Dis. 2018;63:1223\u201334.","journal-title":"J Alzheimers Dis"},{"key":"2398_CR44","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1186\/s12974-015-0434-1","volume":"12","author":"WA Banks","year":"2015","unstructured":"Banks WA, Gray AM, Erickson MA, Salameh TS, Damodarasamy M, Sheibani N, Meabon JS, Wing EE, Morofuji Y, Cook DG, Reed MJ. Lipopolysaccharide-induced blood-brain barrier disruption: roles of cyclooxygenase, oxidative stress, neuroinflammation, and elements of the neurovascular unit. J Neuroinflammation. 2015;12:223.","journal-title":"J Neuroinflammation"},{"key":"2398_CR45","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1177\/030006051204000527","volume":"40","author":"K Kotani","year":"2012","unstructured":"Kotani K, Caccavello R, Taniguchi N, Gugliucci A. Circulating soluble receptor for advanced glycation end products is inversely correlated to oxidized low-density lipoproteins in asymptomatic subjects. J Int Med Res. 2012;40:1878\u201383.","journal-title":"J Int Med Res"},{"key":"2398_CR46","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1093\/ehjqcco\/qcac060","volume":"9","author":"YH Chin","year":"2023","unstructured":"Chin YH, Lim O, Lin C, Chan YY, Kong G, Ng CH, Chong B, Syn N, Chan KE, Muthiah MD, et al. Meta-analysis of the Placebo and Nocebo effects associated with Placebo treatment in randomized trials of lipid-lowering therapies. Eur Heart J Qual Care Clin Outcomes. 2023;9:511\u20139.","journal-title":"Eur Heart J Qual Care Clin Outcomes"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02398-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02398-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T12:03:55Z","timestamp":1734609835000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02398-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2398"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02398-1","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"7 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complied with the principles of Declaration of Helsinki as revised in 1989. The protocol was approved by the Medical Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University. All participants were aware of the research purpose and signed written informed consent forms prior to study initiation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the participants provided written informed consent for the publication of the results of this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"410"}}